As previously reported, Raymond James upgraded Physicians Realty Trust two notches to Strong Buy from Market Perform and established a $22 price target. Analyst Jonathan Hughes views said valuation is attractive and expects the medical office building sector to benefit from increasingly insured individuals, an aging population, and raising demand for healthcare services in lower cost settings.

Mizuho resumed coverage of Healthpeak Properties with a Buy rating and $22 price target. The shares have underperformed healthcare real estate investment trusts year-to-date as investors remain concerned about capital allocation and value creation, challenging fundamentals in life sciences and limited growth opportunities in the company's medical office segment, the analyst tells investors in a research note. However, the firm sees several catalysts during the next few quarters for Healthpeak to re-rate, including selling assets and buying back stock, and an inflection in life science fundamentals in the second half of 2024.